UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Treasury Stock	Paid-in Capital	Management Notes Receivable	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income
Equity, beginning balance at Dec. 31, 2017	$ 606,105	$ 0	$ 57	$ 0	$ 617,014	$ (1,116)	$ (9,920)	$ 70
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stockholders' contribution	0				425	(425)
Interest on management notes receivable	(17)					(17)
Stock-based incentive compensation	438				438
Net income (loss)	(6,851)						(6,851)
Other comprehensive income	1,030							1,030
Equity, ending balance at Mar. 31, 2018	600,705	0	57	0	617,877	(1,558)	(16,771)	1,100
Equity, beginning balance at Dec. 31, 2017	606,105	0	57	0	617,014	(1,116)	(9,920)	70
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(9,369)
Other comprehensive income	1,635
Equity, ending balance at Sep. 30, 2018	599,985	0	57	0	619,110	(1,598)	(19,289)	1,705
Equity, beginning balance at Mar. 31, 2018	600,705	0	57	0	617,877	(1,558)	(16,771)	1,100
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(20)					(20)
Stock-based incentive compensation	668				668
Net income (loss)	(4,309)						(4,309)
Other comprehensive income	418							418
Equity, ending balance at Jun. 30, 2018	597,462	0	57	0	618,545	(1,578)	(21,080)	1,518
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(20)					(20)
Stock-based incentive compensation	565				565
Net income (loss)	1,791						1,791
Other comprehensive income	187							187
Equity, ending balance at Sep. 30, 2018	599,985	0	57	0	619,110	(1,598)	(19,289)	1,705
Equity, beginning balance at Dec. 31, 2018	602,825	0	57	0	619,578	(1,619)	(16,035)	844
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(21)					(21)
Stockholders' redemption	(2,000)				(2,000)
Stock-based incentive compensation	584				584
Net income (loss)	(3,712)						(3,712)
Other comprehensive income	(505)							(505)
Equity, ending balance at Mar. 31, 2019	597,171	0	57	0	618,162	(1,640)	(19,747)	339
Equity, beginning balance at Dec. 31, 2018	602,825	0	57	0	619,578	(1,619)	(16,035)	844
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(60,109)
Other comprehensive income	(8,727)
Equity, ending balance at Sep. 30, 2019	921,682	0	71	(2,399)	1,008,037	0	(76,144)	(7,883)
Equity, beginning balance at Mar. 31, 2019	597,171	0	57	0	618,162	(1,640)	(19,747)	339
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(18)					(18)
Stockholders' redemption	0				(371)
Stock-based incentive compensation	569				1
Net income (loss)	(13,603)						(13,603)
Other comprehensive income	27							27
Equity, ending balance at Jun. 30, 2019	584,146	0	57	0	618,360	(1,287)	(33,350)	366
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(23)					(23)
Repayment of management notes receivable	1,310					1,310
Purchase of BioScrip, Inc.	387,044		14		387,030
Stock-based incentive compensation	2,745				2,745
Exercise of stock options, vesting of restricted stock, and related tax withholdings	(2,497)			(2,399)	(98)
Net income (loss)	(42,794)						(42,794)
Other comprehensive income	(8,249)							(8,249)
Equity, ending balance at Sep. 30, 2019	$ 921,682	$ 0	$ 71	$ (2,399)	$ 1,008,037	$ 0	$ (76,144)	$ (7,883)